Acarbose
Coronary Artery Disorder
University of OxfordSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Coronary Artery Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aspirin Rajaie Cardiovascular Medical and Research Center | Phase 4 | BBB |
Ezetimibe Canadian Collaborative Research Network | Phase 4 | BBB |
Rivaroxaban Sheffield Teaching Hospitals NHS Foundation Trust | Phase 4 | BBB |
Simvastatin University of Washington | Phase 4 | BBB |
Ranolazine OBS Pakistan | Phase 4 | BBB |
View all 48 →
Same molecule, other indications
Acarbose is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →